Literature DB >> 21539694

Central nervous system bleeding in patients with rare bleeding disorders.

S M Siboni1, E Zanon, G Sottilotta, D Consonni, G Castaman, D Mikovic, F Biondo, A Tagliaferri, A Iorio, P M Mannucci, F Peyvandi.   

Abstract

Central nervous system (CNS) bleeding is one of the most severe and debilitating manifestations occurring in patients with rare bleeding disorders (RBDs). The aim of this study was to retrospectively collect data on patients affected with RBDs who had CNS bleeding, to establish incidence of recurrence, death rate, neurological sequences, most frequent location, type of bleeding and efficacy of treatments. Results pertained to 36 CNS bleeding episodes in 24 patients with severe deficiency except one with moderate factor VII (FVII) deficiency. Six patients (25%) experienced a recurrence and two had more than one recurrence. Seven patients (29%) had an early onset of CNS bleeding before the first 2 years of life, others (71%) later in life. In 76% of cases, CNS bleeding was spontaneous. CNS bleeding was intracerebral in 19 cases (53%), extracerebral in 10 (28%) and both intracerebral and extracerebral in two cases (6%). Neurosurgery was performed in 11 cases, in association with replacement therapy in seven cases. Seizures were noted in four patients. Residual psychomotor abnormalities were seen in two patients. No death was recorded. To prevent recurrence, 17/24 patients (71%) were put on secondary prophylaxis. In conclusion, recurrence of CNS bleeding was confirmed to be relatively frequent in patients with severe FV, FX, FVII and FXIII deficiencies. Most patients were managed with replacement therapy alone, surgery being reserved for those with worsening neurological conditions. Our results indicate that some RBDs require early prophylactic treatment to prevent CNS bleeding. Optimal dosage and frequency of treatment need further evaluation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21539694     DOI: 10.1111/j.1365-2516.2011.02545.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.

Authors:  Thomas J Cramer; Kristin Anderson; Karanjia Navaz; Justin M Brown; Laurent O Mosnier; Annette von Drygalski
Journal:  Blood Cells Mol Dis       Date:  2015-11-10       Impact factor: 3.039

2.  Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.

Authors:  Benjamin Briggs; Kiely N James; Shimul Chowdhury; Courtney Thornburg; Lauge Farnaes; David Dimmock; Stephen F Kingsmore
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-12-17

3.  Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit.

Authors:  Erica Sanford Kobayashi; Bryce Waldman; Branden M Engorn; Katherine Perofsky; Erika Allred; Benjamin Briggs; Chelsea Gatcliffe; Nanda Ramchandar; Jeffrey J Gold; Ami Doshi; Elizabeth G Ingulli; Courtney D Thornburg; Wendy Benson; Lauge Farnaes; Shimul Chowdhury; Seema Rego; Charlotte Hobbs; Stephen F Kingsmore; David P Dimmock; Nicole G Coufal
Journal:  Front Pediatr       Date:  2022-01-24       Impact factor: 3.418

4.  Clinical profile of patients with rare inherited coagulation disorders: a retrospective analysis of 67 patients from northern India.

Authors:  Sanjeev Kumar Sharma; Suman Kumar; Tulika Seth; Pravas Mishra; Narendra Agrawal; Gurmeet Singh; Avinash Kumar Singh; Manoranjan Mahapatra; Seema Tyagi; Haraprasad Pati; Renu Saxena
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-02       Impact factor: 2.576

Review 5.  Current understanding in diagnosis and management of factor XIII deficiency.

Authors:  M Naderi; A Dorgalaleh; Sh Tabibian; Sh Alizadeh; P Eshghi; Gh Solaimani
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.